CRSP vs. BEAM
CRSP (CRISPR Therapeutics AG) and BEAM (Beam Therapeutics Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, CRSP returned -16.09%/yr vs -16.23%/yr for BEAM. A 0.70 correlation means they provide meaningful diversification when combined.
Performance
CRSP vs. BEAM - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CRSP achieves a 3.66% return, which is significantly lower than BEAM's 28.17% return.
CRSP
- 1D
- 0.50%
- 1M
- 7.94%
- YTD
- 3.66%
- 6M
- -6.13%
- 1Y
- 22.85%
- 3Y*
- -1.00%
- 5Y*
- -16.09%
- 10Y*
- —
BEAM
- 1D
- 4.07%
- 1M
- 24.06%
- YTD
- 28.17%
- 6M
- 27.26%
- 1Y
- 111.99%
- 3Y*
- 3.76%
- 5Y*
- -16.23%
- 10Y*
- —
CRSP vs. BEAM - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
CRSP CRISPR Therapeutics AG | 3.66% | 33.23% | -37.12% | 54.00% | -46.36% | -50.51% | 179.19% |
BEAM Beam Therapeutics Inc. | 28.17% | 11.77% | -8.89% | -30.40% | -50.92% | -2.39% | 240.17% |
Correlation
The correlation between CRSP and BEAM is 0.76, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.76 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.73 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.75 |
Correlation (All Time) Calculated using the full available price history since Feb 6, 2020 | 0.70 |
The correlation between CRSP and BEAM has been stable across timeframes, ranging from 0.70 to 0.76 - a consistent structural relationship.
Fundamentals
CRSP:
$5.22B
BEAM:
$3.67B
CRSP:
-$6.24
BEAM:
-$0.63
CRSP:
1.21K
BEAM:
27.72
CRSP:
2.88
BEAM:
3.15
CRSP:
$4.10M
BEAM:
$132.27M
CRSP:
-$171.17M
BEAM:
-$84.92M
CRSP:
-$509.21M
BEAM:
-$68.39M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CRSP vs. BEAM — Risk / Return Rank
CRSP
BEAM
CRSP vs. BEAM - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for CRISPR Therapeutics AG (CRSP) and Beam Therapeutics Inc. (BEAM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CRSP | BEAM | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.13 | ||
| Sortino ratioReturn per unit of downside risk | -1.40 | ||
| Omega ratioGain probability vs. loss probability | 1.11 | 1.27 | -0.15 |
| Calmar ratioReturn relative to maximum drawdown | 0.54 | 2.95 | -2.41 |
| Martin ratioReturn relative to average drawdown | 0.89 | 6.34 | -5.46 |
Loading charts...
Drawdowns
CRSP vs. BEAM - Drawdown Comparison
The maximum CRSP drawdown since its inception was -85.11%, roughly equal to the maximum BEAM drawdown of -89.12%. Use the drawdown chart below to compare losses from any high point for CRSP and BEAM.
Loading charts...
Drawdown Indicators
| CRSP | BEAM | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -85.11% | -89.12% | +4.01% |
Max Drawdown (1Y)Largest decline over 1 year | -42.25% | -38.15% | -4.10% |
Max Drawdown (3Y)Largest decline over 3 years | -64.91% | -67.74% | +2.83% |
Max Drawdown (5Y)Largest decline over 5 years | -80.68% | -89.12% | +8.44% |
Current DrawdownCurrent decline from peak | -74.12% | -73.41% | -0.71% |
Average DrawdownAverage peak-to-trough decline | -49.29% | -59.93% | +10.64% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 25.88% | 17.72% | +8.16% |
Volatility
CRSP vs. BEAM - Volatility Comparison
The current volatility for CRISPR Therapeutics AG (CRSP) is 17.92%, while Beam Therapeutics Inc. (BEAM) has a volatility of 23.00%. This indicates that CRSP experiences smaller price fluctuations and is considered to be less risky than BEAM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CRSP | BEAM | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 17.92% | 23.00% | -5.08% |
Volatility (6M)Calculated over the trailing 6-month period | 43.95% | 53.52% | -9.57% |
Volatility (1Y)Calculated over the trailing 1-year period | 62.70% | 75.50% | -12.80% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 60.72% | 76.10% | -15.38% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 64.31% | 80.82% | -16.51% |
Dividends
CRSP vs. BEAM - Dividend Comparison
Neither CRSP nor BEAM has paid dividends to shareholders.
Financials
CRSP vs. BEAM - Financials Comparison
This section allows you to compare key financial metrics between CRISPR Therapeutics AG and Beam Therapeutics Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
CRSP and BEAM have a correlation of 0.76, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
BEAM has higher volatility (23.00%) compared to CRSP (17.92%). In terms of maximum drawdown, CRSP dropped -85.11% vs BEAM's -89.12%.
BEAM currently has the higher Sharpe Ratio (1.49 vs 0.37), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CRSP and BEAM
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer